Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer

Annals of Surgery

Volumn 233, Issue 6, 2001, Pages 819-826

  Bennett, Joseph J ^a,b   Malhotra, Sandeep ^a,b   Wong, Richard J ^a,b   Delman, Keith ^a,b   Zager, Jonathan ^a,b   St Louis, Maryse ^a,b   Johnson, Paul ^a,b   Fong, Yuman ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Neurovir Inc ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; ONCOLYTIC VIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER CELL; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOPATHOGENIC EFFECT; DOSE RESPONSE; EVALUATION; GENE INSERTION; GENE TRANSFER; HERPES SIMPLEX VIRUS; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME;

EID: 0034980245     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-200106000-00012     Document Type: Conference Paper

References (44)

1. Cancer statistics, 2000
2. Clinical perspective of human colorectal cancer metastasis
3. Surgical options in the treatment of hepatic metastasis from colorectal cancer
4. Dormant liver metastases, an experimental study
5. Treatment of colorectal cancer: Hepatic metastasis
6. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer
7. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas
8. Antitumor efficacy of regional oncolytic viral therapy for peritoneally disseminated cancer
9. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multimutated herpes simplex virus type-1 (G207)
10. Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors
11. Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma
12. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma
13. Evidence that the herpes simplex virus type 1 uracil DNA glycosylace is required for efficient viral replication and latency in the murine nervous system
14. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: Construction and evaluation in rodents
15. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: Isolation and characterization of an ICP6 lacZ insertion mutant
16. Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: Characterization of an ICP6 deletion mutant
17. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture
18. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus
19. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial
20. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma
21. Cytokine gene therapy for human tumors
22. T cell- and NK cell-independent inhibition of hepatic metastases by systemic administration of an IL-12-expressing recombinant adenovirus
23. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins
24. Prevention of hepatic tumor metastases in rats with herpes viral vaccines and gamma-interferon
25. Role of NK and T cells in IL-12-induced anti-tumor response against hepatic colon carcinoma
26. Protective immunity is induced in murine colon carcinoma cells by the expression of interleukin-12 or interleukin-18, which activate type 1 helper T cells
27. Role of interleukin-12 (IL-12) as an anti-tumor agent: Experimental biology and clinical application
28. Experimental therapy of human glioma by means of a genetically engineered virus mutant
29. Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1
30. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant
31. Therapeutic efficiency and safety ora second-generation replication-conditional HSV1 vector for brain tumor gene therapy
32. Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5 mutants of herpes simplex virus 1
33. The gamma 34.5 gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programmed cell death in neuronal cells
34. B-myb promoter retargeting of herpes simplex virus gamma 34.5 gene-mediated virulence toward tumor and cycling cells
35. A conserved open reading frame that overlaps the herpes simplex virus thymidine kinase gene is important for viral growth in cell culture
36. Importance of the herpes simplex virus UL24 gene for productive ganglionic infection in mice
37. A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes
38. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors
39. Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes
40. Effects of IL-12 on helper T cell-dependent immune responses in vivo
41. Direct in vitro evidence and in vivo analysis of the antiangiogensis effects of interleukin 12
42. Induction of systemic and herapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12
43. Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12
44. IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts